Pyolytics: A Step Forward to Address Respiratory Hypoxia in Coronavirus Infection

Respiratory failure and increasing hypoxia in the era of coronavirus infection is the cause of fatal outcomes in patients with SARS. The bronchoalveolar obstruction prevents the normal passage of air, resulting in decreased oxygenation. The available methods of oxygenation (ECMO) are often not cost-effective and are not readily available in pandemic settings. Hence, the search for alternatives has prompted the discovery of a new pharmacological group - pyolytics, the use of which is very promising due to its simplicity and availability.